Synchronous primary cancers of the endometrium and ovary.
Simultaneous detection of malignancy in the endometrium and ovary represents an uncommon event. The objective of the study was to clarify the possible factors that influenced on the survival. From 1977 to 2005, totally 27 patients fulfilled the criteria and were included in the study. The medical records and the pathologic reports were reviewed. The histologic determination was followed by the World Health Organization Committee classification, and cancer stage was based on the staging system of the FIGO. The Kaplan-Meier survival analyses were generated and compared by the log-rank test. The incidence of synchronous primary endometrial and ovarian cancers was 3.3% in patients with endometrial cancer and 2.7% in patients with ovarian cancer. The mean survival in the group of similar histology (n= 15) was 63 months, and 48 months in the group of dissimilar histology (n= 12) (P= 0.63). The mean survival in the group of early stage (n= 21) was 68 months and 15 months in the group of advanced stage (n= 6) with statistic significance (P= 0.0003). However, the impact of adjuvant therapy on survival did not reach statistic significance (P= 0.15 for chemotherapy; P= 0.69 for radiotherapy). We conclude that the majority of the patients belonged to concordant endometrioid histology in endometrium and ovary, and it tends to be early stage and low grade with favorable prognosis. The stage had more significant influence on the survival than the histology. Adjuvant therapy should be given especially in patients with advanced stage although the optimal management remained to be determined.
Chiang
Y-C
YC
Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen
C-A
CA
Huang
C-Y
CY
Hsieh
C-Y
CY
Cheng
W-F
WF
D000230:Adenocarcinoma / Q000556:secondary; D018262:Adenocarcinoma, Clear Cell / Q000556:secondary; D000328:Adult; D018269:Carcinoma, Endometrioid / Q000556:secondary; D018284:Cystadenocarcinoma, Serous / Q000556:secondary; D016889:Endometrial Neoplasms / Q000473:pathology* / Q000556:secondary; D005260:Female; D006801:Humans; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000556:secondary; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors